Title:
NUCLEIC ACID MOLECULE FOR TREATMENT OF HEPATITIS B
Document Type and Number:
WIPO Patent Application WO/2018/199338
Kind Code:
A1
Abstract:
The present invention provides: a nucleic acid molecule that effectively inhibits hepatitis B virus gene expression; and a pharmaceutical composition that comprises said nucleic acid molecule and is used for inhibiting hepatitis B virus growth and for treating hepatitis B, hepatic cirrhosis, or hepatic cancer. More specifically, provided is a nucleic acid molecule that includes the nucleotide sequence defined in (i) or (ii) as a sequence for inhibiting the expression of hepatitis B virus gene. (i) Nucleotide sequence represented by SEQ ID NO:2; a nucleotide sequence represented by SEQ ID NO:2, wherein one or two bases are deleted, substituted, inserted, or added; or a nucleotide sequence that has 90% or more identity to the nucleotide sequence represented by SEQ ID NO:2. (ii) Nucleotide sequence represented by SEQ ID NO:1; a nucleotide sequence represented by SEQ ID NO:1, wherein one or two bases are deleted, substituted, inserted, or added; or a nucleotide sequence that has 90% or more identity to the nucleotide sequence represented by SEQ ID NO:1.
Inventors:
CHAYAMA KAZUAKI (JP)
YOSHIMA TADAHIKO (JP)
MIZUTANI TAKAYUKI (JP)
YOSHIMA TADAHIKO (JP)
MIZUTANI TAKAYUKI (JP)
Application Number:
PCT/JP2018/017347
Publication Date:
November 01, 2018
Filing Date:
April 27, 2018
Export Citation:
Assignee:
UNIV HIROSHIMA (JP)
SUMITOMO DAINIPPON PHARMA CO LTD (JP)
BONAC CORP (JP)
SUMITOMO DAINIPPON PHARMA CO LTD (JP)
BONAC CORP (JP)
International Classes:
C12N15/113; A61K9/02; A61K9/06; A61K9/08; A61K9/10; A61K9/14; A61K9/20; A61K9/48; A61K9/70; A61K9/72; A61K31/7105; A61K35/76; A61K47/22; A61K47/54; A61P1/16; A61P31/20; A61P35/00; A61P43/00; C12N15/09
Domestic Patent References:
| WO2012005368A1 | 2012-01-12 | |||
| WO2012017919A1 | 2012-02-09 |
Foreign References:
| JP2013537423A | 2013-10-03 |
Attorney, Agent or Firm:
TAKASHIMA, Hajime et al. (JP)
Download PDF: